收稿日期: 2024-02-19
网络出版日期: 2024-09-13
基金资助
浙江省医药卫生科技计划项目(2024KY1601)
Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma
Received date: 2024-02-19
Online published: 2024-09-13
套细胞淋巴瘤（MCL）是一种少见的B细胞非霍奇金淋巴瘤，兼有惰性淋巴瘤和侵袭性淋巴瘤的临床病理特点，近十几年，针对MCL开发了许多新的治疗方法，其中布鲁顿酪氨酸激酶抑制剂（BTKi）在MCL患者的治疗中显示出良好的疗效，通过结合布鲁顿酪氨酸激酶（BTK）蛋白，BTKi能够阻止B细胞的生长，进而发挥抗肿瘤的作用。目前全球上市了5种BTKi用于治疗MCL：第一代伊布替尼（ibrutinib）和第二代阿卡替尼（acalabrutinib）、泽布替尼（zanubrutinib）、奥布替尼（orelabrutinib）以及非共价BTKi吡托替尼（pirtobrutinib）。该文综述了BTKi治疗MCL临床试验的研究结果，为临床治疗MCL提供参考。
徐思诗 , 叶佩佩 . BTK抑制剂治疗套细胞淋巴瘤的临床研究进展[J]. 实用医学杂志, 2024 , 40(17) : 2363 -2368 . DOI: 10.3969/j.issn.1006-5725.2024.17.002
Mantle cell lymphoma （MCL） is a rare B-cell non-Hodgkin's lymphoma characterized by clinical and pathological features encompassing both indolent and aggressive subtypes. Significant progress has been made in the past decade regarding the development of novel therapeutic options for MCL. Particularly， Bruton's tyrosine kinase inhibitor （BTKi） has exhibited remarkable efficacy in treating patients with MCL by specifically targeting the BTK protein， thereby inhibiting B-cell proliferation and inducing potent anti-tumor effects. Currently， global approval has been granted to five BTK inhibitors for MCL treatment， including the first-generation Ibrutinib， second-generation Acalabrutinib， Zanubrutinib， Orelabrutinib， as well as the non-covalent BTKi Pirtobrutinib. This review provides a comprehensive summary of findings from clinical trials investigating the use of BTKi in MCL treatment and offers valuable insights for clinical practice.
Key words： BTK inhibitor; relapsed; refractory; mantle cell lymphoma; targeted therapy
| 1 | ARMITAGE J O， LONGO D L. Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2495-2506. doi:10.1056/nejmra2202672 |
| 2 | MCCULLOCH R， VISCO C， EYRE T A，et al. Efficacy of R-BAC in relapsed， refractory mantle cell lymphoma post BTK inhibitor therapy［J］. Br J Haematol，2020，189（4）：684-688. doi:10.1111/bjh.16416 |
| 3 | LU T， ZHANG J， MCCRACKEN J M，et al. Recent advances in genomics and therapeutics in mantle cell lymphoma［J］. Cancer Treat Rev， 2024， （122）：102651. doi:10.1016/j.ctrv.2023.102651 |
| 4 | 董佳艺，邵丽娟，郑柱，等. 嵌合抗原受体T细胞联合分子靶向药治疗实体瘤研究进展［J］. 实用医学杂志，2023，39（7）：798-803. |
| 5 | ESTUPI?áN H Y， WANG Q， BERGL?F A，et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib，ibrutinib and zanubrutinib［J］. Leukemia，2021，35（5）：1317-1329. doi:10.1038/s41375-021-01123-6 |
| 6 | KEAM S J. Pirtobrutinib： First Approval［J］. Drugs，2023，83（6）：547-553. doi:10.1007/s40265-023-01860-1 |
| 7 | RULE S， DREYLING M，GOY A，et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib：a pooled analysis from three open‐label studies［J］. Br J Haematol，2017，179（3）：430-438. doi:10.1111/bjh.14870 |
| 8 | DREYLING M， JURCZAK W， JERKEMAN M，et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma：an international，randomised，open-label，phase 3 study［J］. Lancet，2016，387（10020）：770-778. doi:10.1016/s0140-6736(15)00667-4 |
| 9 | ESTUPI?áN H Y， BERGL?F A， ZAIN R，et al. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects［J］. Front Cell Dev Biol，2021，9：630942. doi:10.3389/fcell.2021.630942 |
| 10 | JERKEMAN M， ESKELUND C W， HUTCHINGS M，et al. Ibrutinib， lenalidomide，and rituximab in relapsed or refractory mantle cell lymphoma （PHILEMON）： A multicentre，open-label，single-arm，phase 2 trial［J］. Lancet Haematol，2018，5（3）：e109-e116. doi:10.1016/s2352-3026(18)30018-8 |
| 11 | TAM C S， ANDERSON M A， POTT C，et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma［J］. N Engl J Med，2018， 378（13）：1211-1223. doi:10.1056/nejmoa1715519 |
| 12 | LE GOUILL S， MORSCHHAUSER F， CHIRON D，et al. Ibrutinib， obinutuzumab，and venetoclax in relapsed and untreated patients with mantle cell lymphoma： A phase 1/2 trial［J］. Blood，2021，137（7）：877-887. doi:10.1182/blood.2020008727 |
| 13 | DAVIDS M S， KIM H T， NICOTRA A，et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma： a multicentre phase 1-1b study［J］. Lancet Haematol，2019，6（1）：e38-e47. |
| 14 | MARTIN P， BARTLETT N L， BLUM K A，et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma［J］. Blood， 2019，133（11）：1201-1204. doi:10.1182/blood.2019002741 |
| 15 | WANG M， RAMCHANDREN R， CHEN R，et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma：the safety run-in of the phase 3 SYMPATICO study［J］. J Hematol Oncol， 2021， 14（1）：179. doi:10.1186/s13045-021-01188-x |
| 16 | TIVEY A， SHOTTON R， EYRE T A，et al. Ibrutinib as first line therapy for mantle cell lymphoma：A multicentre，real-world UK study［J］. Blood Adv， 2024，8（5）：1209-1219. |
| 17 | WANG M L， JURCZAK W， JERKEMAN M，et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma［J］. N Engl J Med， 2022，386（26）：2482-2494. doi:10.1056/nejmoa2201817 |
| 18 | Update on IMBRUVICA? （ibrutinib） U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications［EB ］（2023-04-06） ［2024-02-03］ . . |
| 19 | DREYLING M， DOORDUIJN J K， GINE E，et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma （TRIANGLE）： a three-arm，randomised， open-label，phase 3 superiority trial of the European Mantle Cell Lymphoma Network［J］. Lancet，2024，403（10441）：2293-2306. |
| 20 | IZUTSU K， ANDO K， ENNISHI D，et al. Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies：A Japanese phase I study［J］. Cancer Sci， 2021，112（6）：2405-2415. doi:10.1111/cas.14886 |
| 21 | LE GOUILL S， D?UGOSZ-DANECKA M， RULE S，et al. Final results and overall survival data from a phase Ⅱ study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma，including those with poor prognostic factors［J］. Haematologica， 2024，109（1）：343-350. |
| 22 | KIM A I， ARMAND P， REDD R A，et al. Phase I Safety and Preliminary Efficacy of Acalabrutinib，Venetoclax，and Obinutuzumab （AVO） in Patients with Relapsed/Refractory Mantle Cell Lymphoma［J］. Blood， 2023，142（）：3031. doi:10.1182/blood-2023-173103 |
| 23 | BAIRD J H， DEL REAL M M， SONG J Y，et al. CD19-Directed CAR T-Cells （CD19-CAR） Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory （r/r） Mantle Cell Lymphoma （MCL）［J］. Blood，2023，142（）：4840. doi:10.1182/blood-2023-182456 |
| 24 | POH C， CHOW V A， LYNCH R C，et al. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma：A Phase Ⅰ/ⅡStudy of Safety， Efficacy and Immune Correlative Analysis［J］.Blood，2023，142 （）：2129. |
| 25 | VILLA D， LAROUCHE J F， CHEUNG M C，et al. Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma： The Rectangle Trial［J］. Blood，2023，142 （）：3042. doi:10.1182/blood-2023-179375 |
| 26 | HAWKES E A， LEE S T， CHURILOV L，et al. A Window Study of Acalabrutinib & Rituximab， Followed By Chemotherapy & Autograft （ASCT） in Fit Patients with Treatment Naive Mantle Cell Lymphoma （MCL）：First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 “Wamm” Trial［J］. Blood，2023，142（）：735. doi:10.1182/blood-2023-178403 |
| 27 | WANG M， ROBAK T， MADDOCKS K J，et al. Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Na?ve （TN） Mantle Cell Lymphoma （MCL）［J］.Blood，2021，138（）： 2416. doi:10.1182/blood-2021-146615 |
| 28 | HAWKES E A， FLETCHER R， WOOD A，et al. Traverse： A Phase 2， Open-Label， Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma［J］. Blood，2023， 142（）：3054. |
| 29 | ZHOU K， ZOU D， ZHOU J，et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma： a pooled analysis of two clinical trials［J］. J Hematol Oncol，2021，14（1）：167. doi:10.1186/s13045-021-01174-3 |
| 30 | KUMAR A， SOUMERAI J， ABRAMSON J S，et al. A Multicenter Phase 2 Trial of Zanubrutinib，Obinutuzumab，and Venetoclax （BOVen） in Patients with Treatment-Naive， TP53-Mutant Mantle Cell Lymphoma［J］. Blood，2023，142（）：738. doi:10.1182/blood-2023-180069 |
| 31 | HILL H A， QI X， JAIN P，et al. Genetic mutations and features of mantle cell lymphoma： a systematic review and meta-analysis［J］. Blood Adv， 2020，4（13）：2927-2938. doi:10.1182/bloodadvances.2019001350 |
| 32 | DENG L J， ZHOU K S， LIU L H，et al. Orelabrutinib for the treatment of relapsed or refractory MCL：a phase 1/2，open-label， multicenter，single-arm study［J］. Blood Adv， 2023，7（16）：4349-4357. doi:10.1182/bloodadvances.2022009168 |
| 33 | DHILLON S. Orelabrutinib： First Approval［J］. Drugs， 2021，81（4）： 503-507. |
| 34 | ZHANG H， SU L， LIU L，et al. A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab（OLR） in Patients with Untreated Mantle Cell Lymphoma（MCL） in China（POLARIS Study）： Preliminary Analysis on Efficacy，Safety，Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses［J］. Blood， 2023，142（）：736. doi:10.1182/blood-2023-178509 |
| 35 | GOMEZ E B， EBATA K， RANDERIA H S，et al. Preclinical characterization of pirtobrutinib， a highly selective，noncovalent（reversible） BTK inhibitor［J］. Blood， 2023，142（1）：62-72. |
| 36 | MATO A R， SHAH N N， JURCZAK W，et al. Pirtobrutinib in relapsed or refractory B-cell malignancies（BRUIN）：a phase 1/2 study［J］. Lancet， 2021，397（10277）：892-901. doi:10.1016/s0140-6736(21)00224-5 |
| 37 | COHEN J B， SHAH N N， JURCZAK W，et al. Pirtobrutinib in Relapsed/Refractory（R/R） Mantle Cell Lymphoma（MCL） Patients with Prior cBTKi：Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study［J］. Blood，2023，142（）：981. doi:10.1182/blood-2023-181627 |
| 38 | EYRE T A， SHAH N N， DREYLING M，et al. BRUIN MCL-321：phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma［J］. Future Oncol， 2022， 18（36）：3961-3969. |
| 39 | RULE S A， CARTRON G， FEGAN C，et al. Long-term follow-up of patients with mantle cell lymphoma（MCL） treated with the selective Bruton′s tyrosine kinase inhibitor tirabrutinib（GS/ONO-4059）［J］. Leukemia， 2020，34（5）：1458-1461. doi:10.1038/s41375-019-0658-7 |
| 40 | ELGAMAL O A， MEHMOOD A， JEON J Y，et al. Preclinical efficacy for a novel tyrosine kinase inhibitor， ArQule 531 against acute myeloid leukemia［J］. J Hematol Oncol， 2020，13（1）：8. doi:10.1186/s13045-019-0821-7 |
| 41 | WOYACH J A， STEPHENS D M， FLINN I W，et al. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma［J］. Cancer Discov，2024，14（1）：66-75. doi:10.1158/2159-8290.cd-23-0670 |
| 42 | MATO A R， WIERDA W G， AI W Z，et al. NX-2127-001， a First-in-Human Trial of NX-2127， a Bruton′s Tyrosine Kinase-Targeted Protein Degrader， in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies［J］. Blood，2022，140（）： 2329-2332. |
/
| 〈 |
|
〉 |